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Abstract: Network medicine relies on different types of networks: from the molecular level of
protein–protein interactions to gene regulatory network and correlation studies of gene expression.
Among network approaches based on the analysis of the topological properties of protein–protein
interaction (PPI) networks, we discuss the widespread DIAMOnD (disease module detection)
algorithm. Starting from the assumption that PPI networks can be viewed as maps where
diseases can be identified with localized perturbation within a specific neighborhood (i.e., disease
modules), DIAMOnD performs a systematic analysis of the human PPI network to uncover new
disease-associated genes by exploiting the connectivity significance instead of connection density. The
past few years have witnessed the increasing interest in understanding the molecular mechanism of
post-transcriptional regulation with a special emphasis on non-coding RNAs since they are emerging
as key regulators of many cellular processes in both physiological and pathological states. Recent
findings show that coding genes are not the only targets that microRNAs interact with. In fact, there
is a pool of different RNAs—including long non-coding RNAs (lncRNAs) —competing with each
other to attract microRNAs for interactions, thus acting as competing endogenous RNAs (ceRNAs).
The framework of regulatory networks provides a powerful tool to gather new insights into ceRNA
regulatory mechanisms. Here, we describe a data-driven model recently developed to explore the
lncRNA-associated ceRNA activity in breast invasive carcinoma. On the other hand, a very promising
example of the co-expression network is the one implemented by the software SWIM (switch miner),
which combines topological properties of correlation networks with gene expression data in order to
identify a small pool of genes—called switch genes—critically associated with drastic changes in cell
phenotype. Here, we describe SWIM tool along with its applications to cancer research and compare
its predictions with DIAMOnD disease genes.
Keywords: bioinformatics; network medicine; gene co-expression network; regulatory network;
ceRNA; PPI network
1. Network Medicine: An Emergent Paradigm in Medicine
The exploitation of the emerging network-based approaches to medicine enables multiple
potential biological and clinical applications by offering an intuitive and reliable way to explore
systematically the molecular complexity of a particular disease and thus leading to the identification
of disease genes as potential drug targets and biomarkers. A disease is rarely a consequence of an
abnormality in a single gene, but reflects the perturbations of the complex network of intracellular and
intercellular interactions. This entirely new perspective, in which critical biological factors are nearly
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always the result of multiple pathobiological pathways that interact through an interconnected network
to control disease pathobiology, has been able to kick-start a new medical paradigm called “Network
Medicine” [1]. The fundamental tenet of network medicine is to look at diseases as perturbations
within the interactome, i.e., the comprehensive network map of molecular components and their
interactions [1,2]. The overall ambition is both to develop a global understanding of how interactome
perturbations result in disease traits, and to translate computational insights into concrete clinical
applications, such as new drugs and therapies or diagnostic tools. Furthermore, the representation
of biological complex systems as networks enables the visualization of the interactome underlying
structure, revealing new functional roles, and proposing new and fresh interpretations of data.
A network is a set of nodes and edges, where nodes are linked together if a kind of interaction
occurs between them. As witnessed by the last-years increasing number of publications (Figure 1),
most attention has been recently directed towards molecular networks, including:
1. Protein–protein interaction (PPI) networks, whose nodes are proteins that are linked to each
other by physical interactions [3,4];
2. Regulatory networks, whose directed links represent regulatory relationships between a
transcription factor and a gene [5];
3. Co-expression networks, in which genes with similar co-expression patterns are linked [6].
Figure 1. Number of 2012–2018 publications related to network-based approaches to medicine.
The figure shows the number of articles published by year obtained by searching the following specific
keywords in Pubmed: network-based approach, network medicine, biological network.
Table 1 summarizes some of the widespread disease-gene prediction methods/tools based on the
analysis of the topological properties of the above-mentioned molecular networks.
The PPI-network based approaches can be mainly classified into: (i) local methods, based on
searching for direct interactions between candidate genes and known disease genes (e.g., Oti et al. [7],
Genes 2018, 9, 437 3 of 25
GenePANDA [8]); (ii) global methods, that model how the information flow in the cell to assess
the proximity and connectivity between known disease genes and candidate genes (e.g., DADA [9],
DIAMOnD [10], PRINCE [11], ProDiGe [12]). In this review, we provide a detailed description of
DIAMOnD [10], the most used and newest approach at the state of the art.
In the past, a great effort has been devoted to understanding the molecular mechanism of
post-transcriptional regulation with a special emphasis on non-coding RNAs (ncRNAs) since they
are emerging as key regulators of many cellular processes in both physiological and pathological
states [13–16]. This class of RNA species appears really heterogeneous, including the intensively
studied microRNAs (miRNAs)—small non-coding RNAs of 20–22 nucleotides long—as well as the
most recent acknowledged long non-coding RNAs (lncRNAs)—non-protein coding RNAs greater
than 200 nucleotides in length and lacking of extended open reading frames [17–19]. Recent findings
show that coding genes are not the only targets that miRNAs interact with. In fact, there is a pool
of different RNAs competing with each other to attract miRNAs for interactions, thus acting as
competing endogenous RNAs (ceRNAs). This intriguing mechanism, also known as “target mimicry”
process, was first discovered in plants [20]. Crucial triggers of this new layer of post-transcriptional
regulation are “decoys”—or miRNA “sponges”—including both coding and non-coding RNAs, such
as pseudogenes, lncRNAs, large intergenic ncRNAs, and circular RNAs [21–24]. Sponges exert their
decoy activity by recruiting miRNA molecules via base-pairing with miRNA-recognition elements
(MREs), which they share with a target, subsequently causing release of the target from miRNA control.
The framework of regulatory networks provides a powerful tool to gather new insights into ceRNA
regulatory mechanisms. Among computational methods describing miRNA-sponge interactions by
exploiting gene regulatory networks approach, the ceRNA model of Paci et al. [25] stood out as the best
method in terms of the percentage of discovered miRNA-sponge interactions associated with breast
cancer, according to a thorough and comparison study proposed in [26]. In this review, we provide
a detailed description of ceRNA model implemented by Paci et al. [25] along with its application to
human breast invasive carcinoma [27].
The framework of co-expression networks provides a powerful tool to gather biologically relevant
information from the interaction structure underpinning patterns of gene expression, thus accelerating
the interpretation of molecular mechanisms at the root of significant biological processes. A new
promising approach based on the co-expression network is the one implemented by SWIM (SWItch
Miner) [28], a software able to identify key genes in a network of interactions of various sorts
by defining appropriate roles of genes according to their local/global positioning in the overall
network. The latter property being of crucial importance, given that, recently, it has been shown
that genes associated with a disease are localized in specific neighborhoods, or disease modules,
within the interactome [1]. SWIM builds the co-expression network by using the Pearson correlation
coefficient between the expression profiles of any pair of genes. Nodes in this network are RNA
transcripts and a link occurs between two nodes if their expression profiles are highly correlated or
highly anti-correlated. In order to identify disease modules, SWIM makes use of network clustering
algorithms like k-means and, then, assigns a role to each node in the network according to its inter- and
intra-cluster interaction. Understanding diseases in the context of these networks allows to address
some fundamental properties of the disease-specific genes, which are called “switch genes” by SWIM.
In this review, we provide a detailed description of SWIM along with its applications in viticulture [29]
and oncology [28,30].
Notably, another tool based on the co-expression network is WGCNA (Weighted Correlation
Network Analysis) [31], a comprehensive collection of R functions for performing various aspects
of gene co-expression network analysis on high-dimensional data, including functions for network
construction, module detection, gene selection, calculations of topological properties, data simulation
and visualization.
This review is organized as follows: in section 2, we detail DIAMOnD algorithm developed by
Barabasi and co-authors [10] to discover new candidate disease genes associated with a particular
Genes 2018, 9, 437 4 of 25
phenotype; in section 3, we detail the ceRNA model proposed by Paci et al. [25,27] and its application
to human breast cancer; in section 4, we describe the software SWIM (SWItch Miner) [28] and its
applications in viticulture [29] and oncology [28,30].
Table 1. Overview of network-based approaches to medicine.
Method/Tool Brief Description Availability Reference
Protein–Protein
Interaction Network
Oti et al.
It identifies new candidate disease genes by searching for disease proteins
having interaction partners located within loci associated with the same
disease
Prediction
results
available
[7]
GenePANDA
(Gene Prioritizing
Approach using Network
Distance Analysis)
It identifies new candidate disease genes based on their relative distance
to known disease genes in a functional association network
Prediction
results
available
[8]
DADA
(Degree-Aware Disease
Gene Prioritization)
It prioritizes candidate disease genes with respect to a disease of interest
based on network proximity measure, calculated by using Random Walk
with Restarts algorithm [32] with some statistical adjustment
MATLAB
software
package
[9]
DIAMOnD
(DIseAse MOdule
Detection)
It identifies full disease modules around a set of known disease proteins
by performing a systematic analysis of the PPI-network that exploits the
“connectivity significance” instead of local connection density
Python
software
package
[10]
PRINCE
(PRIoritizatioN and
Complex Elucidation)
It prioritizes genes related to a query disease based on their closeness, in
the PPI-network, to genes causing phenotypically similar disorders to
the query disease
Cytoscape
Plug-in [11,33]
ProDiGe
(Prioritization Of Disease
Genes)
It implements a novel machine learning strategy for gene prioritization
based on learning from a set of positive examples (e.g., known
disease genes) and unlabeled examples (e.g., candidate genes), allowing
heterogeneous data integration
MATLAB
software
package
[12]
Regulatory Network
MMI-network
(MiRNA-Mediated
Interactions network)
ceRNA model based on partial association to investigate the role of
lncRNAs as miRNA sponges in human breast cancer. It computes for
each triplet (lncRNA, miRNA, messenger RNA (mRNA)) the difference
between Pearson correlation of (lncRNA, mRNA) and partial correlation
(lncRNA, mRNA|miRNA) to examine the contribution of the miRNA
into the lncRNA/mRNA relationship
Prediction
results
available
[25,27]
PANDA
(Passing Attributes
between Networks for
Data Assimilation)
It implements a message-passing model using multiple sources of
information to predict regulatory relationships, and used it to integrate
protein–protein interaction, gene expression, and sequence motif data
to reconstruct genome-wide, condition-specific regulatory networks in
yeast as a model
MATLAB/
R/Python
software
packages
[34]
Sonawane et al.
It uses PANDA to infer gene regulatory networks for 38 different tissues
by integrating GTEx RNA-sequencing (RNA-seq) data with a canonical
set of transcription factors to target gene edges and protein–protein
interactions
Prediction
results
available
[35]
Co-Expression Network
SWIM
(Switch Miner)
Wizard-like software that integrates gene expression data with network
topological properties for identifying a small pool of genes (i.e., switch
genes) critically associated with drastic changes in cell phenotype
MATLAB
software
package
[28–30]
WGCNA
(Weighted Correlation
Network Analysis)
Collection of R functions for performing weighted correlation
network analysis of large data sets, including functions for network
construction, module identification, topological properties calculation,
data manipulation and visualization
R software
package [31]
2. DIseAse MOdule Detection (DIAMOnD)
Recently, several studies have shown how cellular components associated with a specific disease
are not randomly scattered within the human interactome, but agglomerate in specific regions,
suggesting the existence of specific “disease modules” for each disease. Barabasi et al. [1] proposed a
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research pipeline for the identification and validation of disease modules. In particular, for any specific
disease the pipeline consists of the following steps:
• Interactome reconstruction merges the most up-to-date information on protein–protein
interactions, co-complex memberships, regulatory interactions and metabolic network maps
in the tissue and cell line of interest.
• Disease gene (seed) identification collects the known disease-associated genes obtained from
linkage analysis, genome-wide association studies or other sources, which serve as the seed of the
disease module.
• In disease module identification, the seed genes are placed on the interactome, with the aim of
identifying a subnetwork that contains most of the disease-associated components, exploiting
both the functional and topological modularity of the network.
• Pathway identification can be used in instances in which the number of components contained
in the ascertained disease module is so large that it cannot serve as a tractable starting point for
further experimental work.
• Disease modules are tested for their functional and dynamic homogeneity.
More recently, Barabasi and co-authors proposed a novel algorithm—DIAMOnD (DIseAse
MOdule Detection) [10]—to uncover disease modules associated with a particular phenotype. By
systematically analyzing the protein–protein interactions of 70 diseases, they showed that disease
modules do not coincide with topological communities of densely interconnected proteins and instead
identified the interaction significance as the key quantity to characterize the connection patterns
among disease proteins. To extract disease modules, DIAMOnD algorithm starts from proteins known
to be associated with a particular disease (i.e., seed proteins) and prioritizes the other proteins of
the interactome having a significant fraction of their interactions with seed proteins. In particular,
DIAMOnD encompasses the following steps:
1. For all proteins with at least one connection to any of the seed proteins, it calculates the
“connectivity significance”. Specifically, DIAMOnD uses the hypergeometric distribution to
calculate the statistical significance of having drawn ks seed proteins (out of k total draws) from a
population of N proteins including s0 seed proteins. The hypergeometric distribution is:
p(k, ks) =
(s0ks)(
N−s0
k−ks )
(Nk )
(1)
and then, the “connectivity significance” is obtained as:
p-value(k, ks) =
k
∑
ki=ks
p(k, ki) (2)
In a network view, the population of N proteins corresponds to the nodes of the PPI-network
and k are the nearest neighbors of a certain protein in the network. This set of nearest neighbors
must include ks seed proteins. Thus, p(k, ks) is the probability that a protein with a total of k links
has exactly ks links to seed proteins and p-value(k, ks) is the probability that a protein with a total
of k links has more connections to seed proteins than expected (Figure 2).
2. It ranks the proteins according to their respective p-values. The protein with the highest rank
(i.e., lowest p-value) is called “candidate protein”.
3. It adds the candidate protein to the set of seed proteins, increasing their number from s0 to
s1 = s0 + 1.
4. It iterates steps 1–3 with the expanded set of seed proteins, pulling one protein at a time into the
growing disease module.
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The procedure 1–4 can be repeated until the module spans across the entire network. The order in
which the proteins are being added to the module provide a ranking of all proteins reflecting relevance
association to the disease.
Figure 2. Sketch of step 1 of DIAMOnD. The network corresponds to the interactome where the red
balls are the seed proteins, the orange square is the protein to test with k connections (orange and grey
thick links) including ks links to seed proteins (orange thick links), the grey balls refer to other proteins
in the PPI-network. The sets at top-right correspond to: U is the ensemble of the total number of nodes
in the PPI-network, S is the ensemble of the draw of k proteins, including ks seed proteins (ks = 2 in
this example), P is the ensemble of the seed proteins.
3. miRNA-Mediated Interactions Network: A Competing Endogenous RNA Model Exploiting
the Topological Properties of Regulatory Networks
Recent findings have identified ceRNAs as the drivers in many disease conditions, including
cancers [22,36–39]. They indirectly regulate each other by reducing the amount of miRNAs available
to target messenger RNAs via the binding of MREs [40]. Recently, a computational method [25]
was developed for identifying putative lncRNAs acting as miRNAs sponges in human breast cancer.
In this study [25], the authors used normalized level three RNA- and miRNA- sequencing expression
data of breast cancer adenocarcinoma (brca) from IlluminaHiSeq platform that were retrieved from
TCGA (The Cancer Genome Atlas) [41,42]. The study concerned 72 samples for which the complete
sets of tumor and matched normal profiles (for both RNA-seq and miRNA-seq data) were available.
The computational ceRNA model is based on three hypotheses:
i. RNAs competing for the same miRNA are marked by a highly positive correlation.
ii. Interaction between the RNAs competing for the same miRNA is indirect, i.e., mediated by
miRNA.
iii. RNAs competing for the same miRNA harbor one or more MREs for the miRNA they sponge.
For what concerns the first hypothesis, the top-correlated messenger RNA (mRNA)/lncRNA
pairs in normal and cancer data sets were selected by setting in both cases the correlation threshold to
the 99th percentile of the corresponding overall correlation distribution (Figure 3A right).
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Figure 3. Results of Paci et al. model to predict miRNA sponge interactions in breast invasive carcinoma
[25]. (A) Heatmap showing the sensitivity correlation for the top-correlated mRNA/lncRNA pairs (e.g.,
pairs for which the Pearson correlation between their expression profiles exceeds the 99th percentile of
the overall correlation distribution) in normal breast tissues. Red color corresponds to zero sensitivity
correlation, meaning that the interaction between the selected RNA pairs is direct and not mediated
by miRNAs. Light vertical stripes point to miRNAs that are mediating the interaction, suggesting
putative competing endogenous RNAs. (B) The same as in panel (A) but using data from breast cancer
tissues. (C) The normal MMI-network (1738 nodes and 32,375 edges) built starting from the expression
data of normal breast tissues. Nodes represent both mRNAs and lncRNAs; edges represent miRNAs
that are mediating their interactions. Each pair of linked nodes fulfills two requirements: (i) sensitivity
correlation > 0.3 and (ii) one or more shared MREs, for each miRNA linking them. Colors correspond
to different miRNAs. (D) PVT1 subnetwork analysis. From left to right: the percentage of the miRNAs
sponged by PVT1 with respect to all of its; some nearest neighbors of PVT1 that are well-known cancer
genes; the sponge interactions sub-network of PVT1 (753 nodes and 2169 edges).
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For what concerns the second hypothesis, to investigate the scenario in which specific miRNAs
may mediate the interactions of the top-correlated mRNA/lncRNA pairs, a well-established tool of
multivariate analysis (i.e., the partial correlation) was applied to each selected mRNA/lncRNA pair
with respect to each miRNA in their dataset. In general, the partial correlation (ρXY|Z) measures the
extent to which an observed correlation between two variables X and Y (here, the expression profiles
of a mRNA and a lncRNA) relies on the presence of a third controlling variable Z (here, the expression
profile of a miRNA) and it is computed as:
ρXY|Z =
ρXY − ρXZρZY√
1− ρ2XZ
√
1− ρ2ZY
(3)
where ρXY is the Pearson correlation. Then, for each triplet mRNA/lncRNA/miRNA the sensitivity
correlation S, defined as:
S = ρXY − ρXY|Z (4)
was computed. The XYZ triplets with S > 0.3, corresponding to a drop of about the 30% in the
correlation between XY when Z is removed, were selected. The sensitivity distribution of the
top-correlated mRNA/lncRNA pairs (XY) is plotted removing one miRNA (Z) molecule at time
(Figure 3A left).
For what concerns the third hypothesis, the triplets mRNA/lncRNA/miRNA that are enriched in
binding sites of the shared miRNA (hypergeometric test p-value < 0.01) were selected by performing
a seed match analysis. The minimal pairing requirement to predict a miRNA target recognition is a
perfect match to positions 2–7 (6-mer miRNA seed) at the 5’-end of the mature miRNA sequence [43].
Integrating the results of multivariate statistical analysis and seed match analysis, the so-called
miRNA-mediated interactions (MMI) network was built both in normal (Figure 3C) and cancer tissues
[25]. Nodes in the networks represent mRNAs and lncRNAs with highly correlated expression profiles
while edges represent miRNAs mediating their interactions. Normal MMI-network accounted for
1738 nodes and 32,375 edges (Figure 3C). Linked nodes are required to fulfill the above-mentioned
hypothesis of the ceRNA model, which corresponds to the following mathematical constraints:
i. Matching high values of the Pearson correlation between their expression profiles (ρ > 0.7);
ii. Matching high values of the sensitivity correlation (S > 0.3);
iii. Sharing binding sites for miRNAs (6-mer miRNA seed match).
This study revealed the existence of a complex regulatory network in normal samples that appears
to be missing in tumor samples (and vice-versa), highlighting a marked rewiring in the ceRNA program
between normal and pathological breast tissues (Figure 3B). At the heart of this phenomenon, there
was the recently and widely studied oncogene PVT1 [44–63] that switched from being the first of the
hubs in the normal MMI network to fall outside the list of nodes of the cancer network. In normal
network, PVT1 revealed a net binding preference towards the miR-200 family (Figure 3D), which
antagonized to regulate the expression of hundreds of mRNAs that are known to be related to the
cancer development and progression (e.g., GATA3, CDH1, TP53, TP63, TP73, RUNX1, and RUNX3).
Despite its up-regulation in breast cancer tissues, mimicked by the miR-200 family members, PVT1
stopped working as ceRNA in the cancerous state.
The specific conditions required for a ceRNA landscape to occur are still far from being determined.
However, in a recent study [27], the authors emphasized the importance of the relative concentration
of the ceRNAs, and their related miRNAs. In particular, they focused on the withdrawal of the
PVT1 ceRNA activity functioning as miR-200 sponge in breast cancer tissues, betting on a titration
mechanism as the main culprit (i.e., large changes in the ceRNA expression levels either overcome, or
relieve, the miRNA repression on competing RNAs; similarly, a very large miRNA over-expression
may abolish competition). Firstly, they performed a gene expression and sequence analysis of
PVT1 genomic locus, which revealed the existence of multiple isoforms representing all the possible
Genes 2018, 9, 437 9 of 25
configurations (Figure 4A): missing the binding site (e.g., Iso11 and Iso12 in Figure 4A); hosting
the binding site for all (e.g., Iso1 in Figure 4A) or some members of the miR-200 family (e.g., Iso6
or Iso7 in Figure 4A). By performing the principal component analysis (PCA) using the feature
abundance levels of all the PVT1 isoforms across normal and cancer samples, the authors found that
two principal components (PCs) were able to explain more than the 80% of the variance of the data
(Figure 4B left). In particular, the first PC–explaining about the 60% of the total variance of the analyzed
data—referred to the variation of the TCONS_147501 isoform that, missing the binding site, did not
interact with the miR-200 family; while the second PC—explaining by alone about the 20% of the
total variance—corresponded to the variation of the TCONS_147426 isoform that, hosting the binding
site for the miR-200b/200c/429 cluster, could be act as competitor of the targets of these miRNAs.
By drawing the score plot (Figure 4B right), it emerged that the first PC and the second PC were able
to to separate the contribution of the isoform missing the binding site for any members of the miR-200
family (i.e., TCONS_147501, blue isoform in Figure 4B) and of the isoform hosting the binding site
for the miR-200b/200c/429 cluster (i.e., TCONS_147426, red isoform in Figure 4B) from all the others,
respectively. Then, since the isoform harboring the binding site (i.e., TCONS_147426) and the isoform
missing the binding site for the miR-200 family members (i.e., TCONS_147501) were the only isoforms
that changed, the author evaluated the ratio between the abundance of each one with respect to one
representative member of the miR-200b/200c/429 cluster (i.e., miR-200b) in both normal and cancer
tissues (Figure 4C). From this analysis, they found that only the PVT1 isoform harboring the binding
site for miR-200b showed a drastic decrease in its relative concentration with respect to the miRNA
abundance from normal to cancer tissues, providing a plausibility argument to the breakdown of the
sponge program orchestrated by the oncogene PVT1 (Figure 4C).
Figure 4. Cont.
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Figure 4. Analysis of PVT1 isoforms [27]. (A) Sketch of PVT1 genomic locus as reconstructed by
Cufflinks spans across a genome interval of over 300 kb (i.e., 128,806,789-129,113,603 bases within
the February 2009 human genome build GRCh37/hg19) on the forward strand of chromosome 8.
PVT1 locus gives rise to 91 different variants according to raw RNA-seq data of TCGA (The Cancer
Genome Atlas) for breast invasive carcinoma. The isoform names correspond to an increasing symbolic
numbering and not to the actual nomenclature of the PVT1 variants. Lines represent introns and boxes
(violet and grey) represent exons. Violet boxes correspond to the binding sites for the miR-200 family
members. Note that some isoforms lack such binding sites (e.g., Iso11 and Iso12). (B) (Left) The percent
variability explained by each principal component (PC) shown by the Pareto chart. This chart contains
both bars and a line graph, where individual values are represented in descending order by bars,
and the line represents the cumulative total value. The y-axis represents the percentage of the data
variance explained by each PC, whereas the x-axis represents the principal components that are able to
explain the first 100% of the cumulative distribution. PCA is performed using the variations of all the
isoforms between normal and cancer tissues. (Right) The scatter plot of the projection of the original
data (i.e., the variations of all the isoforms between normal and cancer tissues) onto the first two PCs;
the x-axis contains the first PC while the y-axis contains the second PC. In this plot, it is possible to
group isoforms in three classes: the isoform missing the binding site for the miR-200 family members
(blue isoform, TCONS_147501), the isoform with the seed match for the miR-200b/200c/429 cluster
(red isoform, TCONS_147426), and all the others. The first PC is able to separate the variation of the
blue isoform from the others; the second PC is able to separate the variation of the red isoform from
the others. (C) The ratio between the abundance of the red isoform (TCONS_147426, with the binding
site for the miR-200b/200c/429 cluster) and blue isoform (TCONS_147501, without the binding site)
with respect to the miR-200b in both normal (striped rectangle) and cancer tissues (full boxes). In the
normal tissues only the isoform of PVT1 gene harboring the binding site for the miR-200b/200c/429
cluster acts as a sponge regulator of the miR-200 family members. In cancer tissues, it stops working as
a sponge since its concentration is much lower than the concentration of the miR-200 family members.
4. SWItchMiner (SWIM): A Tool Exploiting the Topological Properties of Gene Co-Expression
Networks
SWItchMiner (SWIM) [28] is a wizard-like software implementation of a network-based model.
By combining topological properties of co-expression networks with genome-wide analysis, SWIM is
able to identify a small pool of genes, called switch genes that are critically associated with drastic
changes in cell phenotype.
4.1. SWIM Algorithm
The algorithm implemented by SWIM [28] is composed of the steps depicted in Figure 5.
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Figure 5. SWIM flowchart. The figure depicts the steps performed by SWIM [28] and shows some
examples of outputs obtained by running SWIM on the grapevine dataset [29].
4.1.1. Differential Gene Expression Analysis
Pre-processing phase. SWIM includes a pre-processing phase (Step 1 in Figure 5) for removing
genes whose expression is mostly zero or change very little. This step requires the selection of two
specific thresholds: the first threshold regards the maximum number of zeros allowed for the expression
values of each gene across samples; the second one concerns the minimum variation—measured by
the Inter Quartile Range (IQR) percentile—allowed for each gene across samples.
Filtering phase. SWIM implements a filtering phase (Step 2 in Figure 5) that allows to remove
genes whose expression between two given conditions (A and B) does not change enough or does
it without statistical significance. This step requires the selection of other two specific thresholds.
Considering the logarithm of the ratio between the average expression of samples in condition A and
the average expression of samples in condition B (log fold-change), the first threshold allows to remove
the genes falling behind, in absolute value, a fixed cutoff on the log fold-change. The second threshold
concerns the smallest probability (p-value) for which the data allow to reject the null hypothesis
(i.e., the means of the two distributions are identical) of the Student’s t-test. Actually, since this
statistical test will be repeated multiple times (as much as the genes under testing), the obtained
p-values must be adjusted. To correct multiple tests, SWIM makes use of False Discovery Rate (FDR)
method [64] and thus the threshold refers to the FDR values. At the end of this phase, the differentially
expressed genes between conditions A and B have been identified.
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4.1.2. Network Analysis
Building the correlation network. SWIM builds a co-expression network of differentially
expressed RNAs based on the Pearson correlation between the expression profiles of gene pairs (Step 3
in Figure 5). In this network, two nodes are connected if the absolute value of the Pearson correlation
for their expression profiles is greater than a given threshold. The choice of this threshold should
reflect a right balance between the number of edges and the number of connected components of the
network: the number of edges should be as small as possible in order to have a manageable network
(pointing towards a higher threshold) and the number of connected components should be as small as
possible in order to preserve the integrity of the network (pointing towards a smaller threshold).
Finding communities in the network. To find communities in the network, SWIM makes use of
the k-means algorithm [65], a method of cluster decomposition whose aim is to partition n objects
(i.e., the nodes of the co-expression network) into N clusters (Step 4 in Figure 5). The quality of
clustering was evaluated by minimizing the sum of the squared error (SSE), depending on the distance
of each object to its closest centroid. A reasonable choice of the number of clusters is suggested by
the position of an elbow in the SSE plot computed as a function of N. As distance measure, it is
used dist(x, y) = 1− ρ(x, y), where ρ(x, y) is the Pearson correlation between expression profiles of
nodes x and y. The k-means algorithm, despite being the most widely used clustering algorithm,
has some intrinsic limitations. Firstly, the number of clusters must be set in advance; secondly, it
guarantees convergence only to a local minimum of SSE; thirdly, the initial position of the centroids is
randomly chosen to cause a dependence of the partitioning on initialization. However, some reasonable
assumptions can be done and are described in the following. There is no strict method to determine
the “correct” number of clusters. Among others, SWIM uses an approach—named “Scree plot”—that
evaluates the behavior of the SSE function to vary the number of clusters. Then, the position of an elbow
in the scree plot—i.e., where the “cliff” reaches a bottom plateau—determines an appropriate number
of clusters. Since finding the global optimum of SSE is theoretically NP-hard [66], it is commonly
assumed that is sufficient to carry out a number of random initialization followed by a selection of the
best separated solution, measured by the lowest SSE [67]. Moreover, the partition with the lowest SSE
is commonly assumed to be reproducible under repeated initializations [67]. Thus, for a given number
of clusters, SWIM allows repeating the clustering many times (replicates), each with a new set of initial
cluster centroid positions. For each replicate, the k-means algorithm performs iterative partitioning
(iterations) until the minimum of the SSE function is reached. Then, the cluster configuration with the
lowest SSE values among all replicates will be chosen, for that number of clusters.
4.1.3. Role assignment to network nodes
Building the heat cartography map. Once the modular structure of the complex network
has been found, roles have to be assigned to each node. This is done by dividing the plan
according to two parameters, the clusterphobic coefficient Kpi and the global within-module degree
zg. The clusterphobic coefficient Kpi measures the “fear” of being confined in a cluster, in analogy
with the claustrophobic disorder. A high value of Kpi denotes nodes having much more external than
internal links. The global within-module degree zg measures how “well-connected” each node is to
other nodes in its own community. In the following, the formal definitions of these parameters for a
generic node i [28]:
Kipi = 1−
(
kini
ki
)2
(5)
zig =
kini − k¯Ci
σCi
(6)
where kini is the number of links of node i to nodes in its module Ci, ki is the total degree of node i,
k¯Ci and σCi are the average and standard deviation of the total degree distribution of the nodes in the
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module Ci. This definition of zg quantifies how much a node is a hub (i.e., degree exceeding 5 [68])
in its community and thus represents a measure of local connectivity. On the contrary, the parameter
Kpi evaluating the ratio of internal to external connections of a node represents a measure of global
connectivity. Note that Kpi = 0 when a node has only links within its module, i.e., it does not
communicate with the other modules (kini = ki); while Kpi is close to 1 when the majority of its
links are external to its own module. According to the global within-module degree zg and the
clusterphobic coefficient Kpi values, the plane is divided into seven regions (R1–R7), each defines a
specific node role [69]. High zg values correspond to nodes that are hubs within their module (local
hubs), while high values of Kpi identify nodes that interact mainly outside their community. Then,
SWIM colors nodes in the cartography according to the average Pearson correlation coefficient (APCC)
between the expression profiles of each node and its nearest neighbors [68]. This representation of
the network is defined as “heat cartography map” (Step 5 in Figure 5). By computing the APCC
of expression over all interaction partners of each hub in PPI networks in yeast, the authors in [68]
concluded that hubs fall into two distinct categories: date hubs that display low co-expression with
their partners (low APCC) and party hubs that have high co-expression (high APCC). In the gene
expression networks, the distribution of APCCs appears to be trimodal [28,29] where, similar to PPI
networks, two peaks represent low (date hubs) and high (party hubs) positive APCC values, but with
the addition of a new third peak which is characteristic of gene expression networks and represents
negative APCC values. Nodes populating this peak are called “fight-club hubs” [29].
Identification of switch genes. Looking at the heat cartography map, SWIM identifies the
so-called “switch genes” (Step 6 in Figure 5): the subset of the fight-club hubs that mainly interact
outside their community (region R4). In particular, they satisfy the following topological and
expression features:
i. Being not a hub in their own cluster (zg < 2.5);
ii. Having many links outside their own cluster (Kpi > 0.8);
iii. Having a negative average weight of their incident links (APCC < 0).
At the end of Step 6, SWIM gives the opportunity to perform further analyses regarding the
evaluation of network robustness, which is the resilience to errors, by studying the effect on the
network connectivity of removing nodes by decreasing degree. In particular, SWIM evaluates the
effect on the average shortest path (the shortest path between two nodes is the minimum number of
edges connecting them and the average shortest path of a network is the average of the shortest paths
for all possible pairs of network nodes) of removing randomly chosen nodes, switch genes, fight-club
hubs, date and party hubs. Since scale-free networks have few hubs and many non-hub nodes, they
are amazingly resistant to a random removal of nodes, while the removal of hubs causes an effect
known as “vulnerability to attack” to allude to the fact that the integrity of the network is destroyed.
4.2. SWIM Applications
SWIM was amenable to detect switch genes in different organisms and cell conditions, leading to
the identification of key players in biologically relevant scenarios, including but not limited to human
cancer [28–30].
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4.2.1. Grapevine Analysis
SWIM was successfully applied in plants [29] for studying the transition between mature to
immature phase of the developmental program of of Vitis Vinifera. In this study, switch genes
resulted to be master regulators of the transcriptome remodeling that marks the developmental
shift of grapevine from immature to mature growth. Specifically, the authors found about one hundred
switch genes in grapevine that appears to be anti-correlated with about 1000 genes (more than 50%
of the entire co-expression network). All switch genes, expressed at low levels in vegetative/green
tissues, showed a significant increase in mature/woody organs, suggesting a potential regulatory role
in the immature-mature transition. Among switch genes, they found many transcription factors like
NAC-domain genes and many targets of tissue-specific miRNAs, such as the NAC33 switch gene and
miRNA-164 whose interaction was experimentally validated. The authors propose a transcriptional
regulatory network in which tissue-specific and stage-specific miRNAs regulate the expression of
several switch genes (Figure 6A). Switch genes appeared to be over-expressed in mature organs and
they are presumably regulated by tissue specific microRNAs with an opposite trend. They resulted
also anti-correlated with thousands of genes that were down-regulated in mature tissue, meaning
that the transition to mature growth in grapevine was mainly due to the suppression of vegetative
pathways such as photosynthesis and cell proliferation rather than the activation of maturation-specific
pathways. The immature fruits grow and make photosynthesis, then stop growing and start ripening
and activate the secondary metabolism like color, aroma and flavor of the fruit. The results of this
study are very important for the winemaking industries because the identification of which genes are
responsible for the ripening can help to face climate changes and thus improve the quality of wine.
Figure 6. Cont.
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Figure 6. SWIM applications in (A) grapevine analysis [29], (B) multi-cancers analysis [28], and
(C) glioblastoma analysis [30]. (A) A sketch of the switch gene regulation mechanism in grapevine.
During the vegetative/green phase of organ development, switch genes are repressed by miRNAs
and vegetative genes are expressed. In the transition to the mature/red phase, these miRNAs are
deactivated, the switch genes are expressed and their anti-correlated vegetative genes are turned off.
The heat map shows the transcription level of positively and negatively correlated genes with a typical
switch, where expression values increase from blue to red. (B) A sketch of the switch gene regulation
mechanism in human cancers. SWIM extracted a set of 100 cancer-recurrent switch genes across four
tumors—breast invasive carcinoma (brca), lung squamous cell carcinoma (lusc), lung adenocarcinoma
(luad), uterine corpus endometrial carcinoma (ucec)—that showed a marked functional enrichment
in cell cycle and specifically on the regulation of the G2-to-M transition. The promoter motif analysis
suggested that two major transcription factors (namely E2F and NFY) lead to the activation of
the switch gene layer of gene regulation. Activation of switch genes in these cancers seems to
predominantly repress several metabolic pathways, possibly leading to the well-known metabolic
rewiring characterizing cancer cells. (C) A sketch of the switch gene regulation mechanism in human
glioblastoma. Glioblastoma subpopulation of self-renewing, stem-like cells has been shown to be
responsible for tumor initiation, progression, resistance to treatment, and relapse. Among switch
genes identified by SWIM involved in the transition from a stem-like to a differentiated phenotype of
glioblastoma cells, FOSL1 stands out as a promising candidate to trigger the differentiation. On one
hand, it has been found positively correlated with genes encoding proteins linked to the focal adhesion
complex and extracellular matrix (ECM) receptor interaction (e.g., integrins, collagen, and signaling
proteins). Conversely, it is negatively regulated with well-known neurodevelopmental transcription
factors (TFs) specific of stem-like identity, including the core set of OLIG2, POU3F2, SALL2, SOX2 [70].
Thus, it could be considered as putative controller of stem-like cell differentiation process by repressing
the core set of neurodevelopmental TFs and by modulating the equilibrium between cell adhesion and
migration.
4.2.2. Multi-Cancer Analysis
SWIM was applied to a large panel of cancer datasets obtained from TCGA [41,42] to identify
switch genes that could be critically associated with the drastic changes in the physiological state
of tissues induced by the cancer development [28]. In this study, the authors found disease-specific
switch genes, as well as common switch genes that were shared among different tumors. The list of
common switch genes encompassed 100 RNA transcripts that appeared all up-regulated in cancer and
enriched in cell cycle, in particular at the transition between the G2 phase and M phase. Moreover, their
promoter regions appeared enriched in three known regulatory motifs: the cell cycle gene homology
(CHR) element, the nuclear transcription factor Y (NFY) binding motif the E2F transcription factor
(E2F) binding motif, that are known to participate in the regulation of progression through the cell cycle.
Finally, the analysis of the functional annotation of their negative nearest neighbor highlighted a general
association of crucial nodes of metabolic process. The authors propose a regulatory network to describe
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the switch gene mechanism in human cancers (Figure 6B). In summary, the list of 100 common switch
genes appear to be over-expressed in cancer tissues, suggesting a their potential role in the malignant
transformation; they are involved in cell cycle, at the G2/M transition; they are anti-correlated to some
metabolic pathways that in turn appear to be switched-off in cancer and they are activated by growth
signals. The activation of switch genes by growth transcription factors could accelerate the late phase
of the cell cycle with a consequent increase of cancer progression and promote the rewiring of some
metabolic pathways, hallmarks of the malignant transformation [71].
The list of disease-specific switch genes identified by SWIM encompassed protein coding genes,
long non-coding, and miRNAs, recovering many known key cancer players, but also many new
potential biomarkers not yet characterized in cancer context. Motivated by the growing interest in
lncRNAs, which appears to hold strong promise as novel biomarkers and therapeutic targets for
cancer [72,73], and by the widespread recognized role of miRNAs as key negative regulators in
many intracellular processes as well as in carcinogenesis [74], in the following we discuss miRNAs,
lncRNAs, and mRNAs acting as switch genes in the multi-cancer analysis across TCGA cancer
datasets, separately.
miRNA-diseasome network. We built a diseasome bipartite network consisting of two disjoint
sets of nodes: one set corresponds to the human cancer types under study (diseases); the other set
corresponds to all miRNAs acting as switch genes in each disease (Figure 7A). A disease and a miRNA
are then connected by a link if that miRNA acts as switch gene in that disease. This representation
allows to highlight which are miRNAs involved in multiple diseases (i.e., grey nodes in Figure 7A) and
which are disease-specific miRNAs for each tumor (i.e., nodes that are colored according to each tumor
type in Figure 7A). We called this network “miRNA-diseasome”, in analogy with the human diseasome
network of [2], where the two disjoints set of nodes corresponds to disorders and disease genes. In this
diseasome bipartite network a link is placed between a disorders and a disease gene if mutations in
that gene lead to the specific disorder. Then, starting from the miRNA-diseasome bipartite network,
we generated a biologically relevant network projection that we called “miRNA-disease network”
(MDN) (Figure 7B). In the MDN nodes represent diseases, and two diseases are connected to each
other if they share at least one miRNA acting as switch gene in both diseases. This representation
provides a disease-centered view of the miRNA-diseasome and allows us to highlight tumors with
the highest number of miRNAs acting as switch genes (i.e., blca that results as a major hub in the
network), as well as tumors with the highest number of shared miRNAs (i.e., blca and ucec).
Figure 7. Comparative analysis of miRNAs acting as switch genes in the large panel of TCGA
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cancer datasets. (A) miRNA-diseasome. The bipartite network is composed of two disjoint sets of
nodes with different size: the larger ones correspond to the analyzed human cancer types from TCGA,
whereas the smaller ones correspond to all miRNAs acting as switch genes. A link occurs between
a tumor type and a miRNA if the miRNA acts as switch gene for that tumor. Different colors are
associated to different tumor types. miRNAs are colored based on the tumor type to which they belong.
Nodes are light gray if the corresponding miRNAs are associated with more than one tumor type.
(B) miRNA-disease network (MDN). The MDN is the projection of the miRNA-diseasome bipartite
network, in which nodes correspond to tumor types (diseases) and two diseases are connected if
there is at least one miRNA that acts as switch gene in both. The width of a link is proportional
to the number of miRNAs that are acting as switch genes in both diseases. The size of a node is
proportional to the number of microRNAs acting as switch genes for that disease. Different node colors
are associated with different diseases. blca: bladder urothelial carcinoma, chol: cholangiocarcinoma,
hnsc: head and neck squamous cell carcinoma, kich: kidney chromophobe, kirc: kidney renal clear
cell carcinoma, kirp: kidney renal papillary cell carcinoma, lihc: liver hepatocellular carcinoma, prad:
prostate adenocarcinoma, thca: thyroid carcinoma.
lncRNA-diseasome network. We performed the same analysis as for miRNAs in order to build a
lncRNA-diseasome bipartite network, where one set of nodes corresponds to the human cancer types
analyzed by SWIM in [28] and the other set corresponds to all lncRNAs acting as switch genes in each
disease (Figure 8A). A disease and a lncRNA are then connected by a link if that lncRNA acts as switch
gene in that disease. Then, starting from the lncRNA-diseasome bipartite network, we generated the
“lncRNA-disease network” (LDN) (Figure 8B), where nodes represent diseases, and two diseases are
connected to each other if they share at least one lncRNA acting as switch genes in both diseases.
Figure 8. Comparative analysis of lncRNAs acting as switch genes in the large panel of TCGA cancer
datasets. (A) lncRNA-diseasome. The bipartite network is composed of two disjoint sets of nodes with
different size: the larger ones correspond to the analyzed human cancer types from TCGA, whereas the
smaller ones correspond to all lncRNAs acting as switch genes. A link occurs between a tumor type and
a lncRNA if the lncRNA acts as switch gene for that tumor. Different colors are associated to different
tumor types. lncRNAs are colored based on the tumor type to which they belong. Nodes are light
gray if the corresponding lncRNAs are associated with more than one tumor type. (B) lncRNA-disease
network (LDN). The LDN is the projection of the lncRNA-diseasome bipartite network, in which nodes
correspond to tumor types (diseases) and two diseases are connected if there is at least one lncRNA
that acts as switch gene in both. The width of a link is proportional to the number of lncRNAs that are
acting as switch genes in both diseases. The size of a node is proportional to the number of lncRNAs
acting as switch genes for that disease. Different node colors are associated with different diseases.
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mRNA-diseasome network. Finally, we built a mRNA-diseasome bipartite network, where one
set of nodes corresponds to the human cancer types analyzed by SWIM in [28] and the other set
corresponds to all mRNAs acting as switch genes in each disease (Figure 9A). Then, as before, starting
from the mRNA-diseasome bipartite network, we generated the “mRNA-disease network” (MRDN)
(Figure 9B), where nodes represent diseases, and two diseases are connected to each other if they share
at least one mRNA acting as switch genes in both diseases.
Figure 9. Comparative analysis of protein-coding genes (mRNAs) acting as switch genes in the large
panel of TCGA cancer datasets. (A) mRNA-diseasome. The bipartite network is composed of two disjoint
sets of nodes with different size: the larger ones correspond to the analyzed human cancer types from
TCGA, whereas the smaller ones correspond to all protein coding genes acting as switch genes. A link
occurs between a tumor type and a mRNA if the mRNA acts as switch gene for that tumor. Different
colors are associated to different tumor types. mRNAs are colored based on the tumor type to which
they belong. Nodes are light gray if the corresponding miRNAs are associated with more than one tumor
type. (B) mRNA-disease network (MRDN). The MRDN is the projection of the mRNA-diseasome bipartite
network, in which nodes correspond to tumor types (diseases) and two diseases are connected if there is
at least one mRNA that acts as switch gene in both. The width of a link is proportional to the number of
mRNAs that are acting as switch genes in both diseases. The size of a node is proportional to the number of
mRNAs acting as switch genes for that disease. Different node colors are associated with different diseases.
4.2.3. Glioblastoma analysis
Glioblastoma multiforme (GBM) is the most frequently diagnosed and aggressive brain tumor
with the 5-years survival rate achieved for only 5% of patients. Several studies identified a
subpopulation of GBM cells with radio/chemotherapy-resistant properties that have a role in driving
tumor initiation, progression, resistance to treatment, and relapse [75]. Due to their abilities of
self-renewal, proliferation, and differentiation into multiple lineages, these cells are named cancer
stem-like cells and are held responsible for carcinogenesis (Figure 6C). The identification of genes
responsible of the stem-like phenotype are going to dominate cancer research scene as effective
and long-lasting therapeutic strategy. In this context, a recent study [70] identified a 4-core of
neurodevelopmental TFs (transcription factors) (i.e., OLIG2, POU3F2, SALL2, SOX2), which are
selectively expressed in glioblastoma stem-like cells and have been shown to be sufficient to fully
reprogram differentiated cells into glioblastoma stem-like cells. In order to computationally identify
genes controlling cancer stem-like cells differentiation and invasion, SWIM was applied to gene
expression profiles from two independent GBM datasets [30], publicly available on the Gene Expression
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Omnibus (GEO) repository: RNA-seq data obtained from stem-like tumor-propagating cells and
differentiated glioblastoma cells (i.e., GSE54792 [70]); Affymetrix HG-U133 Plus 2.0 microrarrays
expression data from glioblastoma stem-like cell lines, the corresponding primary tumors, and
conventional glioma cell lines (i.e., GSE23806 [76])).
SWIM identified the FOS like transcription factor FOSL1 as the most promising switch gene
(Figure 6C) shared from both datasets [30]. Indeed, FOSL1 fulfills very interesting features that made
it eligible as new potential therapeutic target: it is down-regulated in stem-like cells; it is highly
negatively correlated with the 4-core TFs (OLIG2, POU3F2, SALL2, SOX2); the promoter regions of the
4-core TFs were found to harbor a consensus binding motif for FOSL1; it was found to act as repressor
transcription factor [77]; it is positively correlated with genes encoding proteins crucial for cell-matrix
adhesion and cell motility (e.g., actin, collagen, fribonectin, and several integrins), which can influence
cell adhesion dynamics and migration, and thus the cancer invasiveness.
Taken together these considerations prompted the authors to bet on FOSL1, which could promote
the differentiation process of GBM stem-like cells by repressing the 4-core TFs and consequently halted
cancer growth and invasion. This should allow for anticipation of care as well as the reduction of the
social impact of diseases and the restraint of health costs.
4.3. SWIM Switch Genes towards DIAMOnD Disease Genes
Next we explore the performance of SWIM on human breast invasive carcinoma. Since the
full set of disease proteins is unknown, we cannot assess the performance directly in terms of
true positives/negatives. We therefore compare the results obtained by SWIM with the known
disease-associated genes and with the DIAMOnD disease genes. SWIM was applied to breast invasive
carcinoma expression data from high-throughput RNA-seq downloaded from TCGA data portal. Data
correspond to normalized level three data from RNASeq Version 2 created by using MapSplice [78] to
do the alignment and RSEM [79] to perform the quantification and normalization. The study concerned
103 samples for which the complete sets of tumor and matched normal profiles were available. By
running SWIM, we obtained 257 switch genes and we selected for this comparison only the 195 switch
genes that are coding RNAs. The known disease-associated genes for breast neoplasms disease (in
total s0 = 40 seed proteins) were provided by DIAMOnD paper [10] that integrated data from OMIM
(Online Mendelian Inheritance in Man) [80] and GWAS (Genome-Wide Association Studies). Finally,
the DIAMOnD disease genes were retrieved by running DIAMOnD algorithm for breast neoplasms
disease and retaining the first 500 new disease genes. In total, we considered 540 seed genes, including
the 40 breast neoplasm associated genes and the first 500 DIAMOnD disease genes.
We compared the performance of SWIM switch genes to seed genes as well as to random
expectation for the same number of genes drawn randomly from the network. The performance
is based on the number of switch genes that are considered true positives. To quantify the statistical
significance of a given number of true positives at a given iteration step i, we used a sliding window
approach: at each iteration step i the same number of seed genes was considered. We used genes in the
interval [s0 + (i− 1)] until the sliding window spans across the entire set of 540 seed genes and count
the number of true positives among switch genes. The statistical significance of an observed number is
then determined using the hypergeometric distribution. For breast neoplasms disease, we found that
switch genes are significantly enriched (p-value <0.05) in seed genes until 175 iterations (Figure 10A),
significantly higher than random expectation (Figure 10B). This results is extremely encouraging since
the authors of DIAMOnD claim in the paper [10] that the first ∼200 DIAMOnD genes are found to
participate in important seed pathways at a rate similar to the one within the seed proteins themselves.
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Figure 10. Performance of SWIM in human breast invasive carcinoma. (A) Enrichment p-values of
switch genes in seed genes obtained by running SWIM for breast invasive carcinoma. (B) Enrichment
p-values for a subset of genes drawn randomly from the network in seed genes.
5. Conclusions
In the last decade, the great advances in high-throughput technologies have led to massive
amounts of genomic, transcriptomic, proteomic and metabolomic data capable to provide new
opportunities for identifying potential biomarkers and developing effective treatments for human
diseases. The availability of this huge amount of data has revolutionized biomedical science and, in
particular, cancer genomics, but only the amount is not enough. If in the past there was a difficulty
in collecting genetic data, today the challenge is to give them meaning and it is therefore essential to
use effective informatics solutions capable of managing, analyzing and integrating these biological
“Big Data”. The need to take on this new challenge has paved the way for a paradigm shift towards the
development of temporal and spatial multi-level models, from molecular machineries to single cells,
whole organism and individuals, including the environment, to reveal the underlying links between
components. This new type of medical paradigm is called “Network Medicine”. Rather than trying
to understand pathogenesis into a reductionist framework, network medicine entwines the many
facets of disease in many different types of networks: from the physical interactions acting in a cell
to the information flow through biological components. The representation of complex systems as
networks is of paramount importance for visualizing the interactome underlying structure, revealing
new functional roles, and proposing new and fresh interpretations of data. Networks can be obtained
from any sort of information: known protein–protein interactions, gene expression profiles, functional
annotation, etc. In this review, we focused on three different classes of approaches that use different
types of interaction networks to infer novel cancer genes: methods using PPI networks, methods using
regulatory networks and methods using co-expression networks.
One important bias in the methods that predict cancer genes is the direct or indirect incorporation
of prior knowledge. Methods using PPI networks suffer more from this problem compared with
methods using co-expression and/or regulatory networks. In fact, many proteins or genes have
been extensively studied and hence have a higher number of connections in the protein networks.
Moreover, since network biology is still far from completing the human interactome, PPI networks are
suffering from false negatives (i.e., missing interactions) and false positives (i.e., false interactions) [1].
In the future, much computational effort is needed to complete the human interactome and increase
its confidence.
Finally, network-based approaches using PPI networks are restricted to mutations that affect
protein coding regions of the genome, thus they cannot be used to predict novel cancer genes among
ncRNAs. Although the other two classes of approaches discussed in this review do not suffer of this
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bias, they lack the capability to integrate different data collections. In the future, we expect that the
development of more accurate computational tools will be able to overcome this limitation.
This review provides a limited view of the landscape of the existing approaches that using
network theory to deal with issues related to medicine, but it has the potential to stimulate the growth
of new methods as well as the improvement of the existing ones. This will fuel advances in network
medicine supporting the planning of disease prevention and treatment.
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